Author(s): Magalhães, João Duarte ; Fão, Lígia ; Vilaça, Rita ; Cardoso, Sandra Morais ; Rego, A. Cristina
Date: 2021
Persistent ID: https://hdl.handle.net/10316/103764
Origin: Estudo Geral - Universidade de Coimbra
Subject(s): neurodegenerative disorders; autophagy; mitophagy mitochondrial dysfunction; mutant proteins; therapeutic strategies
Macroautophagy, a quality control mechanism, is an evolutionarily conserved pathway of lysosomal degradation of protein aggregates, pathogens, and damaged organelles. As part of its vital homeostatic role, macroautophagy deregulation is associated with various human disorders, including neurodegenerative diseases. There are several lines of evidence that associate protein misfolding and mitochondrial dysfunction in the etiology of Alzheimer's, Parkinson's, and Huntington's diseases. Macroautophagy has been implicated in the degradation of different protein aggregates such as Aβ, tau, alpha-synuclein (α-syn), and mutant huntingtin (mHtt) and in the clearance of dysfunctional mitochondria. Taking these into consideration, targeting autophagy might represent an effective therapeutic strategy to eliminate protein aggregates and to improve mitochondrial function in these disorders. The present review describes our current understanding on the role of macroautophagy in neurodegenerative disorders and focuses on possible strategies for its therapeutic modulation.
